imipramine has been researched along with cimetidine in 70 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 13 (18.57) | 18.7374 |
1990's | 2 (2.86) | 18.2507 |
2000's | 20 (28.57) | 29.6817 |
2010's | 33 (47.14) | 24.3611 |
2020's | 2 (2.86) | 2.80 |
Authors | Studies |
---|---|
Creveling, CR; Daly, JW; Lewandowski, GA; McNeal, ET | 1 |
Brown, TH; Ganellin, CR; Griffiths, R; Jones, M; Mitchell, RC; Rana, KK; Saunders, D; Smith, IR; Sore, NE; Young, RC | 1 |
Blake, JF; Curatolo, WJ; Lombardo, F | 1 |
Conway, SJ; Ganapathy, V; George, RL; Huang, W; Leibach, FH; Wang, H; Wu, X | 1 |
Carrupt, PA; Crivori, P; Cruciani, G; Testa, B | 1 |
Topliss, JG; Yoshida, F | 1 |
Conway, SJ; Ganapathy, ME; Ganapathy, V; Huang, W; Kekuda, R; Leibach, FH; Wang, H; Wu, X | 1 |
Faller, B; Wohnsland, F | 1 |
Gao, F; Lombardo, F; Shalaeva, MY; Tupper, KA | 1 |
Alvarez-Pedraglio, A; Colmenarejo, G; Lavandera, JL | 1 |
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 2 |
Akazawa, M; Inui, K; Okuda, M; Saito, H; Urakami, Y | 1 |
Chang, TK; Ensom, MH; Kiang, TK | 1 |
Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Alimuddin, M; Bulloch, D; Dahl, R; Grant, D; Lee, N; Peacock, M | 1 |
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Altenbach, RJ; Brioni, JD; Carr, TL; Chandran, P; Cowart, MD; Esbenshade, TA; Honore, P; Hsieh, GC; Lewis, LG; Liu, H; Manelli, AM; Marsh, KC; Milicic, I; Miller, TR; Strakhova, MI; Vortherms, TA; Wakefield, BD; Wetter, JM; Witte, DG | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
Du-Cuny, L; Mash, EA; Meuillet, EJ; Moses, S; Powis, G; Song, Z; Zhang, S | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
Campillo, NE; Guerra, A; Páez, JA | 1 |
García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
Glen, RC; Lowe, R; Mitchell, JB | 1 |
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
Hayashi, S; Kato, A; Mizuno, K; Morita, A; Nakata, E; Ohashi, K; Yamamura, K | 1 |
Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
Giacomini, KM; Kido, Y; Matsson, P | 1 |
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Chen, ZF; Huang, SL; Huang, ZS; Liang, H; Qin, JK; Tang, H; Zhao, HT; Zhao, LZ; Zhong, SM | 1 |
Barber, S; Dew, TP; Farrell, TL; Poquet, L; Williamson, G | 1 |
Chen, ZF; Liang, H; Tang, H; Wang, ZY; Zhao, HT; Zhong, SM | 1 |
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Chen, L; Fei, J; Mei, Y; Ren, S; Yan, SF; Zeng, J; Zhang, JZ | 1 |
Anzini, M; Brogi, S; Butini, S; Campiani, G; Cappelli, A; Caselli, G; Castriconi, F; Gemma, S; Giordani, A; Giorgi, G; Giuliani, G; Lanza, M; Letari, O; Makovec, F; Manini, M; Mennuni, L; Valenti, S | 1 |
Belyakov, S; Dambrova, M; Kazoka, H; Kuznecovs, J; Lebedev, A; Liepinsh, E; Mishnev, A; Orlova, N; Ponomaryov, Y; Vavers, E; Veinberg, G; Vikainis, S; Vilskersts, R; Vorona, M; Zvejniece, L | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Andrisano, V; Bartolini, M; Clos, MV; Di Pietro, O; Juárez-Jiménez, J; Lavilla, R; Luque, FJ; Muñoz-Torrero, D; Pérez, B; Ramón, R; Viayna, E; Vicente-García, E | 1 |
Artursson, P; Mateus, A; Matsson, P | 1 |
Clos, MV; Di Pietro, O; Espargaró, A; Juárez-Jiménez, J; Lavilla, R; Luque, FJ; Muñoz-Torrero, D; Pérez, B; Pérez-Areales, FJ; Sabaté, R | 1 |
Clos, MV; Di Pietro, O; Espargaró, A; Galdeano, C; Guillou, C; Lamuela-Raventós, RM; Luque, FJ; Muñoz-Torrero, D; Pérez, B; Pérez-Areales, FJ; Ragusa, IM; Sabaté, R; Vallverdú-Queralt, A; Viayna, E | 1 |
Artigas, A; Clos, MV; Gbedema, SY; Kelly, JM; Muñoz-Torrero, D; Pérez, B; Sola, I; Taylor, MC; Wright, CW | 1 |
Berenguer, D; Clos, MV; Di Pietro, O; Fisa, R; Kelly, JM; Lanzoni, A; Lavilla, R; Muñoz-Torrero, D; Pérez, B; Riera, C; Sayago, H; Sola, I; Taylor, MC; Viayna, E; Vicente-García, E | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Bednarski, M; Gunia-Krzyżak, A; Marona, H; Nitek, W; Pękala, E; Powroźnik, B; Słoczyńska, K; Walczak, M; Waszkielewicz, AM; Żesławska, E | 1 |
Alencar, N; Di Pietro, O; Esteban, G; Juárez-Jiménez, J; Luque, FJ; Muñoz-Torrero, D; Pérez, B; Sola, I; Solé, M; Szałaj, N; Unzeta, M; Vázquez, J; Viayna, E | 1 |
Artigas, A; Clos, MV; Kelly, JM; Muñoz-Torrero, D; Pérez, B; Pérez-Areales, FJ; Sola, I; Taylor, MC; Viayna, E; Wright, CW | 1 |
Chen, W; Huangli, Y; Qin, J; Shen, Y; Tang, H; Wang, L; Wei, S | 1 |
Filipek, B; Gunia-Krzyżak, A; Marona, H; Nitek, W; Pańczyk, K; Pękala, E; Rapacz, A; Słoczyńska, K; Waszkielewicz, AM; Żelaszczyk, D; Żesławska, E | 1 |
Chen, EC; Chien, HC; Giacomini, KM; Huang, Y; Khuri, N; Liang, X; Sali, A; Stecula, A; Yee, SW | 1 |
Andrisano, V; Barniol-Xicota, M; Bartolini, M; De Simone, A; Espargaró, A; Muñoz-Torrero, D; Pérez, B; Pérez-Areales, FJ; Pivetta, D; Pont, C; Sabate, R; Sureda, FX; Turcu, AL; Vázquez, S | 1 |
Guo, HF; Jin, J; Li, ZR; Liu, ZY; Xie, ZS; Xue, ST; Yi, H; Zhang, L | 1 |
Brea, JM; Companys-Alemany, J; Griñán-Ferré, C; Johnson, JW; Kurnikova, MG; Loza, MI; Pallàs, M; Patel, DS; Pérez, B; Phillips, MB; Soto, D; Sureda, FX; Turcu, AL; Vázquez, S | 1 |
Alhaider, AA; Mustafa, AA | 1 |
Bianchine, JR; Gerber, MC; Gerber, N; Tejwani, GA | 1 |
Dhawan, KN; Gulati, A; Gupta, GP; Nath, C | 1 |
Miller, ME; Perry, CJ; Siris, SG | 1 |
Koike, Y; Spina, E | 1 |
Bobo, L; Pieper, JA; Self, TH; Stewart, CF; Waldon, SL; Warner, C; Wells, BG | 1 |
Henauer, SA; Hollister, LE | 1 |
Abernethy, DR; Greenblatt, DJ; Shader, RI | 1 |
Macklin, M; Miller, DD | 1 |
Baud, F; Bismuth, C; Elkhouly, M; Galliot, M; Pontal, PG | 1 |
Bondoux, D; Emami, S; Gespach, C; Haimart, M; Launay, JM; Mutel, V; Oset-Gasque, MJ | 1 |
Andren, PE; Goodwin, RJ; Gustavsson, L; Källback, P; Schintu, N; Shariatgorji, M; Svenningsson, P | 1 |
3 review(s) available for imipramine and cimetidine
Article | Year |
---|---|
UDP-glucuronosyltransferases and clinical drug-drug interactions.
Topics: Clinical Trials as Topic; Drug Interactions; Enzyme Activation; Enzyme Induction; Glucuronides; Glucuronosyltransferase; Humans; Pharmaceutical Preparations; Pharmacogenetics; Polymorphism, Genetic | 2005 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Drug interactions with cimetidine: an update.
Topics: Absorption; Acetaminophen; Adrenergic beta-Antagonists; Analgesics, Opioid; Animals; Anti-Bacterial Agents; Anticoagulants; Anticonvulsants; Aspirin; Aziridines; Benzodiazepines; Benzoquinones; Cimetidine; Drug Interactions; Humans; Ibuprofen; Imipramine; Kinetics; Lidocaine; Liver Circulation; Pituitary Gland; Procaine; Xanthines | 1985 |
2 trial(s) available for imipramine and cimetidine
Article | Year |
---|---|
The effect of ranitidine and cimetidine on imipramine disposition.
Topics: Administration, Oral; Adult; Analysis of Variance; Cimetidine; Double-Blind Method; Drug Interactions; Humans; Imipramine; Kinetics; Male; Random Allocation; Ranitidine | 1986 |
Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability.
Topics: Administration, Oral; Adult; Biological Availability; Cimetidine; Drug Interactions; Half-Life; Humans; Imipramine; Injections, Intravenous; Kinetics | 1984 |
65 other study(ies) available for imipramine and cimetidine
Article | Year |
---|---|
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Anesthetics, Local; Animals; Batrachotoxins; Calcium Channel Blockers; Cyclic AMP; Guinea Pigs; Histamine H1 Antagonists; In Vitro Techniques; Ion Channels; Neurotoxins; Sodium; Tranquilizing Agents; Tritium | 1985 |
Development of a new physicochemical model for brain penetration and its application to the design of centrally acting H2 receptor histamine antagonists.
Topics: Algorithms; Animals; Blood-Brain Barrier; Brain; Chemical Phenomena; Chemistry, Physical; Clonidine; Guinea Pigs; Histamine H2 Antagonists; Imipramine; Pyrilamine; Structure-Activity Relationship | 1988 |
Computation of brain-blood partitioning of organic solutes via free energy calculations.
Topics: Animals; Blood-Brain Barrier; Brain; Cattle; Cells, Cultured; Endothelium, Vascular; Membrane Lipids; Microcirculation; Molecular Conformation; Molecular Structure; Monte Carlo Method; Permeability; Pharmaceutical Preparations; Software; Solubility; Thermodynamics | 1996 |
Structural and functional characteristics and tissue distribution pattern of rat OCTN1, an organic cation transporter, cloned from placenta.
Topics: Amino Acid Sequence; Animals; Base Sequence; Carnitine; Carrier Proteins; Cloning, Molecular; DNA, Complementary; Humans; Membrane Proteins; Membrane Transport Proteins; Molecular Sequence Data; Organic Cation Transport Proteins; Placenta; Rats; RNA, Messenger; Solute Carrier Proteins; Structure-Activity Relationship; Symporters; Tetraethylammonium; Tissue Distribution | 2000 |
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
Topics: Blood-Brain Barrier; Databases, Factual; Models, Chemical; Molecular Conformation; Multivariate Analysis; Permeability; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Amiloride; Animals; Binding, Competitive; Carbon Radioisotopes; Cations; Cloning, Molecular; DNA-Binding Proteins; DNA, Complementary; Dopamine Agents; Exons; Gene Expression Regulation; HeLa Cells; Herbicides; Humans; In Situ Hybridization; Introns; Kidney; Mice; Niacinamide; Octamer Transcription Factor-3; Oocytes; Pigment Epithelium of Eye; RNA, Messenger; Tetraethylammonium; Transcription Factors; Tritium; Xenopus laevis | 2000 |
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
Topics: Alkanes; Humans; Hydrogen-Ion Concentration; Intestinal Absorption; Membranes, Artificial; Octanols; Permeability; Pharmaceutical Preparations; Solubility; Water | 2001 |
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
Topics: 1-Octanol; Chromatography, High Pressure Liquid; Pharmaceutical Preparations; Solubility; Water | 2001 |
Cheminformatic models to predict binding affinities to human serum albumin.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Tricyclic; Chromatography, Affinity; Cyclooxygenase Inhibitors; Databases, Factual; Humans; Hydrophobic and Hydrophilic Interactions; Penicillins; Pharmaceutical Preparations; Protein Binding; Quantitative Structure-Activity Relationship; Reproducibility of Results; Serum Albumin; Steroids | 2001 |
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
Topics: Blood Proteins; Chemical Phenomena; Chemistry, Physical; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding | 2002 |
cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney.
Topics: Alternative Splicing; Amino Acid Sequence; Base Sequence; Cations; Cell Line; Cloning, Molecular; DNA, Complementary; Genetic Variation; Humans; Kidney; Molecular Sequence Data; Organic Cation Transport Proteins; Organic Cation Transporter 2; Tetraethylammonium; Tissue Distribution; Transfection | 2002 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Determination of log D via automated microfluidic liquid-liquid extraction.
Topics: Automation; Biopharmaceutics; Microfluidic Analytical Techniques; Pharmacokinetics | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzofurans; Carrageenan; Disease Models, Animal; Drug Design; Drug Evaluation, Preclinical; Humans; Hyperalgesia; Ligands; Mice; Molecular Structure; Pain; Peritonitis; Quinazolines; Rats; Receptors, G-Protein-Coupled; Receptors, Histamine; Receptors, Histamine H4; Stereoisomerism; Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
Topics: Antineoplastic Agents; Blood Proteins; Caco-2 Cells; Cell Membrane Permeability; Computer Simulation; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Phosphoproteins; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Quantitative Structure-Activity Relationship | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: de
Topics: Analgesics; Animals; Benzimidazoles; Drug Design; Drug Evaluation, Preclinical; Humans; Microsomes, Liver; Neuralgia; Nociceptin Receptor; Pyrroles; Rats; Receptors, Opioid; Structure-Activity Relationship | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
Topics: Drug Interactions; HEK293 Cells; High-Throughput Screening Assays; Humans; Kidney; Ligands; Models, Molecular; Molecular Structure; Organic Cation Transport Proteins; Organic Cation Transporter 2; Polymorphism, Genetic; Prescription Drugs; Protein Binding; Small Molecule Libraries; Structure-Activity Relationship | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Hybrids of oxoisoaporphine-tacrine congeners: novel acetylcholinesterase and acetylcholinesterase-induced β-amyloid aggregation inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Animals; Aporphines; Blood-Brain Barrier; Butyrylcholinesterase; Cholinesterase Inhibitors; Electrophorus; Horses; Humans; Models, Biological; Tacrine | 2011 |
Predicting phenolic acid absorption in Caco-2 cells: a theoretical permeability model and mechanistic study.
Topics: Artificial Intelligence; Caco-2 Cells; Cell Membrane Permeability; Cinnamates; Enterocytes; Humans; Hydrophobic and Hydrophilic Interactions; Intestinal Absorption; Kinetics; Models, Biological; Molecular Conformation; Osmolar Concentration; Phenols | 2012 |
Novel oxoisoaporphine-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Aporphines; Binding Sites; Blood-Brain Barrier; Butyrylcholinesterase; Cholinesterase Inhibitors; Humans; Membranes, Artificial; Models, Molecular; Molecular Structure; Permeability; Protein Binding | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
Topics: Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kinetics; Microsomes, Liver; Models, Molecular; Molecular Dynamics Simulation; Substrate Specificity | 2013 |
Synthesis and structure-activity relationship studies in serotonin 5-HT(1A) receptor agonists based on fused pyrrolidone scaffolds.
Topics: Animals; Area Under Curve; Humans; Intestinal Absorption; Ligands; Male; Metabolic Clearance Rate; Models, Chemical; Models, Molecular; Molecular Structure; Protein Binding; Protein Structure, Tertiary; Pyrrolidinones; Radioligand Assay; Receptor, Serotonin, 5-HT1A; Receptors, Serotonin, 5-HT3; Serotonin 5-HT1 Receptor Agonists; Structure-Activity Relationship | 2013 |
Synthesis and biological evaluation of 2-(5-methyl-4-phenyl-2-oxopyrrolidin-1-yl)-acetamide stereoisomers as novel positive allosteric modulators of sigma-1 receptor.
Topics: Acetamides; Allosteric Regulation; Animals; Rats; Rats, Wistar; Receptors, sigma; Sigma-1 Receptor; Stereoisomerism; Structure-Activity Relationship | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
1,2,3,4-Tetrahydrobenzo[h][1,6]naphthyridines as a new family of potent peripheral-to-midgorge-site inhibitors of acetylcholinesterase: synthesis, pharmacological evaluation and mechanistic studies.
Topics: Acetylcholinesterase; Animals; Binding Sites; Blood-Brain Barrier; Butyrylcholinesterase; Cholinesterase Inhibitors; Drug Design; Electrophorus; Humans; Membranes, Artificial; Models, Biological; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Structure; Naphthyridines; Permeability; Protein Binding | 2014 |
A high-throughput cell-based method to predict the unbound drug fraction in the brain.
Topics: Animals; Brain; Dialysis; HEK293 Cells; High-Throughput Screening Assays; Humans; Pharmaceutical Preparations; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2014 |
Tetrahydrobenzo[h][1,6]naphthyridine-6-chlorotacrine hybrids as a new family of anti-Alzheimer agents targeting β-amyloid, tau, and cholinesterase pathologies.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cholinesterase Inhibitors; Cholinesterases; Dose-Response Relationship, Drug; Humans; Models, Molecular; Molecular Structure; Naphthyridines; Structure-Activity Relationship; Tacrine; tau Proteins; Tauopathies | 2014 |
Shogaol-huprine hybrids: dual antioxidant and anticholinesterase agents with β-amyloid and tau anti-aggregating properties.
Topics: Acetylcholinesterase; Aminoquinolines; Amyloid beta-Peptides; Antioxidants; Catechols; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Heterocyclic Compounds, 4 or More Rings; Humans; Molecular Structure; Protein Aggregates; Protein Aggregation, Pathological; Structure-Activity Relationship; tau Proteins | 2014 |
Synthesis and antiprotozoal activity of oligomethylene- and p-phenylene-bis(methylene)-linked bis(+)-huprines.
Topics: Antimalarials; Antiprotozoal Agents; Humans; Molecular Structure; Structure-Activity Relationship | 2014 |
Multicomponent reaction-based synthesis and biological evaluation of tricyclic heterofused quinolines with multi-trypanosomatid activity.
Topics: Acetylcholinesterase; Animals; Antiprotozoal Agents; Cell Line; Cell Survival; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Electrophorus; Leishmania infantum; Molecular Structure; Parasitic Sensitivity Tests; Quinolines; Rats; Structure-Activity Relationship; Trypanosoma brucei brucei; Trypanosoma cruzi | 2015 |
Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.
Topics: Amino Alcohols; Animals; Anticonvulsants; Chemistry, Physical; Dose-Response Relationship, Drug; Drug Design; Epilepsy; Male; Mice; Microsomes, Liver; Molecular Structure; Pilocarpine | 2016 |
Design, synthesis and biological evaluation of N-methyl-N-[(1,2,3-triazol-4-yl)alkyl]propargylamines as novel monoamine oxidase B inhibitors.
Topics: Dose-Response Relationship, Drug; Drug Design; Humans; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pargyline; Structure-Activity Relationship | 2016 |
Synthesis and biological evaluation of N-cyanoalkyl-, N-aminoalkyl-, and N-guanidinoalkyl-substituted 4-aminoquinoline derivatives as potent, selective, brain permeable antitrypanosomal agents.
Topics: Aminoquinolines; Brain; Dose-Response Relationship, Drug; Molecular Structure; Parasitic Sensitivity Tests; Structure-Activity Relationship; Trypanocidal Agents; Trypanosoma brucei brucei | 2016 |
Multitarget-directed oxoisoaporphine derivatives: Anti-acetylcholinesterase, anti-β-amyloid aggregation and enhanced autophagy activity against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Aporphines; Autophagy; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Humans; Molecular Structure; Protein Aggregates; Structure-Activity Relationship; Tumor Cells, Cultured | 2016 |
Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH
Topics: Amino Alcohols; Animals; Anticonvulsants; Crystallography, X-Ray; Disease Models, Animal; Dose-Response Relationship, Drug; Electroshock; Mice; Models, Molecular; Molecular Structure; Rats; Seizures; Structure-Activity Relationship | 2017 |
Discovery of Competitive and Noncompetitive Ligands of the Organic Cation Transporter 1 (OCT1; SLC22A1).
Topics: Drug Discovery; HEK293 Cells; Humans; Ligands; Molecular Docking Simulation; Organic Cation Transporter 1; Small Molecule Libraries | 2017 |
A novel class of multitarget anti-Alzheimer benzohomoadamantane‒chlorotacrine hybrids modulating cholinesterases and glutamate NMDA receptors.
Topics: Acetylcholinesterase; Adamantane; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Humans; Molecular Structure; Neuroprotective Agents; Receptors, N-Methyl-D-Aspartate; Structure-Activity Relationship; Tacrine | 2019 |
Substituted benzothiophene and benzofuran derivatives as a novel class of bone morphogenetic Protein-2 upregulators: Synthesis, anti-osteoporosis efficacies in ovariectomized rats and a zebrafish model, and ADME properties.
Topics: Animals; Benzofurans; Bone Morphogenetic Protein 2; Caco-2 Cells; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Mice; Mice, Inbred BALB C; Molecular Structure; Osteoporosis; Ovariectomy; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Thiophenes; Zebrafish | 2020 |
Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Caenorhabditis elegans; Disease Models, Animal; Memantine; Mice; Receptors, N-Methyl-D-Aspartate | 2022 |
Acceleration of rat brain beta-adrenoceptor subsensitivity following the coadministration of histamine receptor antagonists with imipramine.
Topics: Animals; Brain; Chlorpheniramine; Cimetidine; Drinking Behavior; Drug Interactions; Female; Guinea Pigs; Heart; Histamine Antagonists; Imipramine; In Vitro Techniques; Isoproterenol; Propranolol; Ranitidine; Rats; Receptors, Adrenergic, beta | 1989 |
Role of central histaminergic mechanism in behavioural depression (swimming despair) in mice.
Topics: Animals; Atropine; Central Nervous System; Cimetidine; Depression; Desipramine; Disease Models, Animal; Histamine; Imidazoles; Imipramine; Impromidine; Male; Mice; Motor Activity; Pyrilamine; Receptors, Histamine H2 | 1988 |
Psychosis in association with combined cimetidine and imipramine treatment.
Topics: Adult; Cimetidine; Depressive Disorder; Drug Therapy, Combination; Female; Gastroesophageal Reflux; Humans; Imipramine; Psychoses, Substance-Induced | 1987 |
Differential effects of cimetidine and ranitidine on imipramine demethylation and desmethylimipramine hydroxylation by human liver microsomes.
Topics: Cimetidine; Dealkylation; Desipramine; Humans; Hydroxylation; Imipramine; In Vitro Techniques; Kinetics; Microsomes, Liver; Ranitidine | 1986 |
Cimetidine-imipramine interaction: case report and comments.
Topics: Cimetidine; Depressive Disorder; Drug Interactions; Drug Therapy, Combination; Female; Humans; Imipramine; Male; Middle Aged; Peptic Ulcer | 1984 |
Cimetidine interaction with imipramine and nortriptyline.
Topics: Adult; Biological Availability; Cimetidine; Desipramine; Drug Interactions; Humans; Imipramine; Kinetics; Male; Nortriptyline | 1984 |
Cimetidine-imipramine interaction: a case report.
Topics: Adult; Cimetidine; Depressive Disorder; Desipramine; Drug Interactions; Female; Guanidines; Half-Life; Humans; Imipramine; Metabolic Clearance Rate | 1983 |
[Prolonged high plasma imipramine levels after acute intoxication (author's transl)].
Topics: Adult; Cimetidine; Critical Care; Female; Humans; Imipramine; Liver; Metronidazole | 1982 |
Increase of human platelet serotonin uptake by atypical histamine receptors.
Topics: Adult; Aminoquinolines; Biological Transport; Blood Platelets; Cimetidine; Cyclic AMP; Dimaprit; Famotidine; Female; Histamine Antagonists; Histidine; Humans; Imipramine; Impromidine; In Vitro Techniques; Male; Metiamide; Middle Aged; Models, Biological; Platelet Aggregation; Receptors, Histamine; Serotonin | 1994 |
Controlled-pH tissue cleanup protocol for signal enhancement of small molecule drugs analyzed by MALDI-MS imaging.
Topics: Animals; Brain; Cimetidine; Hydrogen-Ion Concentration; Imipramine; Male; Mice; Pharmaceutical Preparations; Rats; Rats, Wistar; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2012 |